Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir

F M Mattes; E G Hainsworth; A F Hassan-Walker; A K Burroughs; P Sweny; P D Griffiths; V C Emery

doi:10.1086/425905

Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir

J Infect Dis. 2005 Jan 1;191(1):89-92. doi: 10.1086/425905. Epub 2004 Nov 29.

Authors

F M Mattes¹, E G Hainsworth, A F Hassan-Walker, A K Burroughs, P Sweny, P D Griffiths, V C Emery

Affiliation

¹ Centre for Virology, Division of Infection and Immunity, Royal Free and University College Medical School, London NW32QG, UK.

PMID: 15593008
DOI: 10.1086/425905

Abstract

The availability of valganciclovir (VGCV) has significantly simplified the treatment of human cytomegalovirus (HCMV) infection after solid-organ transplantation. We show that there was no difference in the kinetics of the decrease in HCMV load after preemptive therapy with VGCV in 22 solid-organ transplant recipients (T1/2=2.16 days), compared with that in 23 patients treated with intravenous ganciclovir (GCV) (T(1/2) = 1.73 days; P=.63). Preemptive therapy with VGCV provides control of HCMV replication that is comparable to that achieved with preemptive intravenous therapy with GCV.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Adult
Antiviral Agents / administration & dosage
Antiviral Agents / therapeutic use*
Cytomegalovirus / drug effects*
Cytomegalovirus Infections / drug therapy
Cytomegalovirus Infections / prevention & control*
Cytomegalovirus Infections / virology
Female
Ganciclovir / administration & dosage
Ganciclovir / analogs & derivatives*
Ganciclovir / therapeutic use*
Humans
Injections, Intravenous
Kinetics
Male
Middle Aged
Retrospective Studies
Transplants*
Valganciclovir
Viral Load
Virus Replication / drug effects

Substances

Antiviral Agents
Valganciclovir
Ganciclovir